AGC Biologics News and Resources

AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO), announced a strategic service agreement with CompleCure to support the development of a novel anti-cancer therapeutic. The therapy, based on Antibody Mimetics Drug Conjugate (AMDC) technology, represents a new approach

NEC Bio Therapeutics, a German biotechnology firm based in Mannheim, is collaborating with AGC Biologics to enhance the production of NECVAX-NEO1. This vaccine, designed to be delivered orally, targets patient-specific tumor neoantigens using a bacteria-based DNA platform. It aims to

Essential Pharma has entered into a strategic agreement with AGC Biologics for the production of Hu14.18, a humanized monoclonal antibody. This antibody is currently under development for the treatment of high-risk neuroblastoma (HRNB), a rare and aggressive form of cancer that

AGC Biologics, a global biopharmaceutical CDMO, and BioConnection, a specialised contract manufacturing organisation (CMO), have announced a new partnership to provide comprehensive biopharmaceutical development and manufacturing services. This collaboration, effective from 22nd May 2024, aims to streamline drug substance and

AGC Biologics, a Seattle-based biopharma contract manufacturer, has announced plans to lay off just under 4% of its global workforce. The company, which employs more than 2,500 workers worldwide, confirmed in a statement that it has had to reduce positions

AGC Biologics, a biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Milan site to begin commercial manufacturing of Orchard Therapeutics’ Lenmeldy. Lenmeldy (atidarsagene autotemcel) is a hematopoietic stem